Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Barbara Ruepp"'
Autor:
Meredith M Regan, Barbara A Walley, Gini F Fleming, Prudence A Francis, Marco A Colleoni, István Láng, Henry L Gómez, Carlo A Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered Stearns, Hervé R Bonnefoi, Silvana Martino, Charles E Geyer, Claudio Chini, Alessandro M Minisini, Simon Spazzapan, Thomas Ruhstaller, Eric P Winer, Barbara Ruepp, Sherene Loi, Alan S Coates, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
Publikováno v:
Cancer Research. 82:GS2-05
Background The updated combined SOFT+TEXT analysis, after 9 years median follow-up (MFU), revealed that adjuvant E+OFS vs T+OFS significantly improved disease-free survival (DFS) and distant recurrence-free interval (DRFI) but not overall survival (O
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Autor:
Olivia, Pagani, Barbara A, Walley, Gini F, Fleming, Marco, Colleoni, István, Láng, Henry L, Gomez, Carlo, Tondini, Harold J, Burstein, Matthew P, Goetz, Eva M, Ciruelos, Vered, Stearns, Hervé R, Bonnefoi, Silvana, Martino, Charles E, Geyer, Claudio, Chini, Fabio, Puglisi, Simon, Spazzapan, Thomas, Ruhstaller, Eric P, Winer, Barbara, Ruepp, Sherene, Loi, Alan S, Coates, Richard D, Gelber, Aron, Goldhirsch, Meredith M, Regan, Prudence A, Francis
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb081c4bd1ec56269065c4f686c173a
https://hdl.handle.net/11390/1243971
https://hdl.handle.net/11390/1243971
Autor:
Prudence A, Francis, Gini F, Fleming, István, Láng, Eva M, Ciruelos, Hervé R, Bonnefoi, Meritxell, Bellet, Antonio, Bernardo, Miguel A, Climent, Silvana, Martino, Begoña, Bermejo, Harold J, Burstein, Nancy E, Davidson, Charles E, Geyer, Barbara A, Walley, James N, Ingle, Robert E, Coleman, Bettina, Müller, Fanny, Le Du, Sibylle, Loibl, Eric P, Winer, Barbara, Ruepp, Sherene, Loi, Marco, Colleoni, Alan S, Coates, Richard D, Gelber, Aron, Goldhirsch, Meredith M, Regan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Autor:
Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, Enrico Silini, Jan von der Thüsen, Nesa Marti, Karerina Vervita, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Paul Baas, Isabelle Opitz, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Barbara Ruepp, Urania Dafni, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Eric Verbeken, Birgit Weyenand, Liesbet Peeters, Marcello Tiseo, Enrico Maria Silini, Luigi Ventura, Letizia Gnetti, Paolo Carbognani, Fatemeh B. Zaeimi, Sven Seiwerth, Marko Jakopovic, Felipe Cardenal, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Paraskevi Boura, Steven Gray, Mutaz Mohammed Nur, Anne-Marie Baird, Martin Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts
Publikováno v:
Modern Pathology, 35(12), 1888-1899. SPRINGERNATURE
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355b5c339b724ea833e0f7b1c96df40e
https://doi.org/10.1038/s41379-022-01145-0
https://doi.org/10.1038/s41379-022-01145-0
Autor:
Richard D. Gelber, Erika Hitre, Andrea Gombos, Alan S. Coates, Alastair M. Thompson, Sole Investigators, Barbara Ruepp, J Chirgwin, Bettina Müller, Marie-Pascale Graas, Stefan Aebi, Subrina Farah, Joaquín Gavilá, Patrick Neven, K. Ribi, A Courtois, Christian Marth, E Abdi, Per Karlsson, Harold J. Burstein, Katsumasa Kuroi, Seamus O'Reilly, A. Goldhirsch, Thomas Ruhstaller, S. Loibl, Manuela Rabaglio, Marco Colleoni, G. Jerusalem, Giulia Viale, C Kamby, Sherene Loi, Edda Simoncini, Meredith M. Regan
Publikováno v:
Annals of Oncology. 32:1256-1266
BACKGROUND Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET). In anima
Autor:
Linda Coate, C.M. Yeo, G. Dimopoulou, J. de Castro, H. Roschitzki-Voser, Martin Früh, Solange Peters, E. Nadal, Rolf A. Stahel, S.M.S. Hashemi, Ross A. Soo, R. Bernabé, M. Provencio, Byoung Chul Cho, M.A. Sala, Sinead Cuffe, Barbara Ruepp, J-Y. Han, R. Garcia Campelo, Enric Carcereny
Publikováno v:
Annals of Oncology. 32:942-944
Autor:
Bettina Müller, Per Karlsson, Stefan Aebi, Giuseppe Viale, Andrea Gombos, Edda Simoncini, Meredith M. Regan, Joaquín Gavilá, Christian Marth, Richard D. Gelber, Thomas Ruhstaller, Subrina Farah, Guy Jerusalem, Erika Hitre, Jacquie Chirgwin, Angelo Di Leo, Harold J. Burstein, Barbara Ruepp, Alan S. Coates, Aron Goldhirsch, Sibylle Loibl, Katsumasa Kuroi, Patrick Neven, Alastair M. Thompson, Seamus O'Reilly, Marie-Pascale Graas, Claus Kamby, Manuela Rabaglio, Marco Colleoni
Publikováno v:
Cancer Research. 80:P5-12
Background: In animal models of hormone receptor positive (HR+) breast cancer, acquired resistance to continued letrozole was shown to be reversed by estrogen-induced apoptosis. We hypothesized that the rise in estrogen levels during short treatment
Autor:
Barbara Ruepp, Rupert Bartsch, Andrea Gombos, Frances M. Boyle, Giuseppe Viale, Anita Hiltbrunner, Thomas Bachelot, Martine Piccart-Gebhart, Caitlin Mahoney, Debora Fumagalli, Rina Hui, Theodora Goulioti, Fabrice Andre, Marco Colleoni, Carmen Comune, Magdelena Weber, Michelle Jenkins, Stefan Aebi, Stefania Andrighetto, Stamatina Fournarakou, Meredith M. Regan, Colleen King, Angelo Di Leo, Alan S. Coates, Rita Hui, Aron Goldhirsch, Mario Campone, Per Karlsson, Rolf A. Stahel, Vassiliki Karantza, Hui Huang, Laura Biganzoli, Hervé Bonnefoi, Sabrina Ribeli-Hofmann, Roswitha Kammler, Magdalena Sánchez-Hohl, Karolyn Scott, Patrick Schneier, Giuseppe Curigliano, Ingrid Kössler, Sherene Loi, Heather Findlay, Richard D. Gelber, Holly Shaw, Guy Jerusalem, Susan Fischer, Anita Giobbie-Hurder, Daniela Celotto, Manuela Rabaglio-Poretti, Rita Pfister, Michela Frapolli, Monica Greco, Adriana Gasca, Mark J. Smyth, Jaime A. Mejia, Karen N. Price, Heidi Roschitzki, Rudolf Maibach
Publikováno v:
The Lancet Oncology. 20:371-382
Summary Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tum
Autor:
W.-D. Janthur, Solange Peters, R. Shah, E. Nadal, David Gilligan, Sanjay Popat, R. López Castro, H. Roschitzki-Voser, Arup Roy, S. Rusakiewicz, A. Pope, James Spicer, Alessandra Curioni-Fontecedro, Patricia Fisher, Igor Letovanec, Varvara Polydoropoulou, Mary O'Brien, Oliver Gautschi, A. Gasca-Ruchti, Rolf A. Stahel, Urania Dafni, R. García Campelo, Barbara Ruepp
Publikováno v:
Annals of oncology, vol. 31, no. 12, pp. 1734-1745
Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6f837ec9c55fa71b6f276b35f45c97
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf